Opinion

Video

Additional Considerations With PBC Therapies

Panelists discuss how recent FDA regulatory actions regarding obeticholic acid have raised concerns about its long-term safety profile and accessibility, leading health care teams to develop strategies for supporting patients through treatment transitions while navigating insurance coverage and access challenges for newer primary biliary cholangitis (PBC) therapies.

Video content above is prompted by the following:

  1. How have recent FDA actions regarding obeticholic acid influenced perceptions of its long-term use in PBC treatment, and what broader implications might these regulatory actions have for patients and providers?
  2. How can health care teams support patients in navigating potential access or coverage challenges that may arise due to regulatory changes affecting PBC therapies, especially when considering a switch to newer treatments?
Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
4 experts are featured in this series.